Intravitreal bevacizumab for diabetic macular edema
[ X ]
Tarih
2012
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Purpose: To evaluate the effects of intravitreal bevacizumab administration on visual acuity (VA), intraocular pressure (IOP) and central foveal thickness (CFT) in patients with diabetic macular edema. Materials and Methods: İntravitreal bevacizumab injection was applied to 39 eyes of 35 patients that presented our clinic with diabetic macular edema, between December 2007 and December 2009. Before and 1 month after injection of 1,25 mg/ml bevacizumab VA,IOP and CFT was measured for each patient. On the second month,the second injection was applied to 29 eyes, and on the third month the third injection was applied to 12 eyes with persistent macular edema. Results: The mean VA increased from 0.206±0.17 to 0.294±22.1 month after first injection (p<0.05). The mean VA was 0.285±0.23 and 0.417±0.31 after second and third injections, respectively. The difference was statistically significant. The mean CMT was reduced from 464.5±115.35 to 332.11±127.60, 1 month after first injection (p<0.05). The mean CMT was 402.50±124.00 and 370.0±142.31 after second and third injections, respectively. The mean IOP was 13.11±2.80 mmHg before first injection, was 13.31±3.22, 13.72±3.04,14.27±2.72 mmHg after first, second and third injections respectively. Conclusion: There was significant difference between the mean IOPs after second and third injections.
Açıklama
Anahtar Kelimeler
Bevacizumab, Diabetic Macular Edema, Intravitreal İnjection
Kaynak
Retina-Vitreus
WoS Q Değeri
Scopus Q Değeri
N/A
Cilt
20
Sayı
1
